BB Biotech AG
ISIN-No.: CH0038389992
YTD: -11.76%
Active share: 78.16
Anzahl Positionen: 23
New innovative drugs and technologies are powering sustainable momentum in the biotech sector
Focus on profitable companies and small and mid-cap companies with strong pipelines
Attractive dividend policy; Dividend payment of 5% p.a.
Indexed performance (as at: 20.05.2025)
Share price: CHF 29.55 (20.05.2025)
NAV: CHF 34.05 (20.05.2025)
Rolling performance (20.05.2025)
| Share Price | NAV | Benchmark | |
| 20.05.2024 - 20.05.2025 | -25.09% | -13.90% | -13.98% |
| 20.05.2023 - 20.05.2024 | -1.48% | 4.45% | 8.94% |
| 20.05.2022 - 20.05.2023 | -15.37% | 2.85% | 6.57% |
| 20.05.2021 - 20.05.2022 | -25.83% | -28.16% | -15.69% |
Annualized performance (20.05.2025)
| Share Price | NAV | Benchmark | |
| 1 year | -25.09% | -13.90% | -13.98% |
| 3 years | -14.52% | -2.57% | -0.36% |
| 5 years | -11.06% | -6.67% | -2.26% |
| 10 years | -2.05% | -1.76% | 0.35% |
| Since Inception p.a. | 8.99% | 9.48% | 8.28% |
Cumulative performance (20.05.2025)
| Share Price | NAV | Benchmark | |
| 1M | 11.30% | 9.92% | 5.51% |
| YTD | -11.76% | -13.80% | -11.93% |
| 1 year | -25.09% | -13.90% | -13.98% |
| 3 years | -37.55% | -7.51% | -1.07% |
| 5 years | -44.34% | -29.18% | -10.78% |
| 10 years | -18.69% | -16.31% | 3.51% |
| Since Inception | 1'410.54% | 1'639.36% | 1'127.24% |
Annual performance
| Share Price | NAV | Benchmark | |
| 2024 | -13.53% | 2.97% | 7.56% |
| 2023 | -18.15% | -7.39% | -4.79% |
| 2022 | -24.29% | -11.00% | -9.09% |
| 2021 | 8.34% | -11.45% | 2.98% |
Facts & Key figures
Investment Focus
BB Biotech actively invests worldwide in fast growing companies developing and marketing innovative biotech drugs. At least 90% of its shareholdings must be in listed companies, while always holding more than 50% of its assets in equity investments. Show moreShow less
Investment suitability & Risk
Low risk
High risk
General Information
| Investment Manager | Bellevue Asset Management AG |
| Custodian | Bank Julius Bär AG |
| Fund Administrator | Bellevue Asset Management AG |
| Auditor | Deloitte AG |
| Launch date | 09.11.1993 |
| Year end closing | 31. Dec |
| Management Fee | 1.10% |
| ISIN number | CH0038389992 |
| Valor number | 3838999 |
| Bloomberg | BION SW Equity |
| WKN | A0NFN3 |
Legal Information
| Legal form | Incorporate company |
| SFDR category | Article 8 |
Key data (30.04.2025, base currency CHF)
| Beta | 1.29 |
| Volatility | 31.36 |
| Tracking error | 14.42 |
| Active share | 78.16 |
| Correlation | 0.91 |
| Sharpe ratio | 0.04 |
| Information ratio | 0.01 |
| Jensen's alpha | -0.08 |
| No. of positions | 23 |
Portfolio as at 31.03.2025
Positions
Market capitalization
Breakdown by sector
Currency
Benefits & Risks
Benefits
- Unique opportunity for European investors to access the global biotech sector, a non-cyclical growth industry that is strongly supported by increasing demand, driven by demographic trends and life style changes.
- New innovative drugs and technologies are powering sustainable momentum in the biotech sector.
- Focus on a diversified portfolio of profitable companies as well as small and midcap companies with strong pipelines.
- Management Team with strong scientific and medical expertise. Renowned Board of Directors.
- Attractive dividend policy; Dividend payment of 5% p.a.
Risks
- BB Biotech actively invests in equities. Equities are subject to strong price fluctuations and so are also exposed to the risk of price losses.
- Biotech equities can be subject to sudden substantial price movements owning to market, sector or company factors.
- BB Biotech invests in foreign currencies, which means a corresponding degree of currency risk against the reference currency.
- The price investors pay or receive, like other listed shares, is determined by supply and demand and may be at a discount or premium to the underlying net asset value of the Company.
- BB Biotech may take a leverage of up to 15%, which may lead to even higher price movements compared to the underlying market.
Review / Outlook
BB Biotech reported its first quarter results on April 25th. First quarter of 2025 was characterized by the elevated volatility across global financial markets, driven by increasing political uncertainty and evolving trade policies. Against the turbulent macroeconomic backdrop, the biotech sector faced a particularly challenging quarter. Healthcare policy uncertainties coupled with sustained market volatility continued to weigh heavily on the industry.
BB Biotech remains focused on its mission: to invest in companies developing breakthrough therapies that can transform patient outcomes. We remain committed to innovation while recognizing that the sector’s fragile structural recovery requires heightened awareness of emerging risks.
BB Biotech reported a net loss of CHF 241 mn for the quarter and a payout of nearly CHF 100 mn in dividends in March compared to a net profit of CHF 260 mn in the first quarter last year.
In the first quarter we initiated a new position in Akero Therapeutics following the company’s breakthrough Phase II results in patients with cirrhotic MASH. On the exit side, we closed our positions in Intra-Cellular, Fate Therapeutics, Sage Therapeutics and Arvinas.
The full quarterly report can be read here: https://report.bbbiotech.ch/Q125/en
Please find below selected highlights from a few of BB Biotech´s portfolio companies:
Revolution Medicine (+14.2%, in USD) announced on April 27 new clinical data for zoldonrasib in patients with KRAS G12D mutant non-small cell lung cancer. The results demonstrated acceptable safety and tolerability and encouraging initial antitumor activity in patients with non-small cell lung cancer.
Argenx (+9.0%, in USD) announced on April 10 that the FDA approved a new option to self-inject Vyvgart Hytrulo with a prefilled syringe for the treatment of adult patients with generalized myasthenia gravis. On April 28 Argenx announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended European Commission (EC) approval of Vyvgart for the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyradiculoneuropathy (CIPD) after prior treatment with corticosteroids or immunoglobulins.
Alnylam (-2.5%, in USD) announced April 28 that the Committee for Medicinal Products for Human Use (CHMP) recommends approval of Vutrisiran for the treatment of ATTR-CM (hereditary transthyretin amyloidosis in adult patients with cardiomyopathy). Vutrisiran is currently approved in the European Union under the brand name Amvuttra for the treatment of hATTR (hereditary transthyretin-mediated amyloidosis with polyneuropathy).
Dokumente
Show moreShow less
